Close this search box.

We are creating some awesome events for you. Kindly bear with us.

New Hi-Tech RNA Pilot Manufacturing Facility Launched in NSW

COVID-19 has highlighted the important work of the University’s researchers, and how their vital partnerships with government and industry can accelerate real-world outcomes. The University of Sydney announced that is part of the NSW Government’s announcement of a first-of-its-kind Australian pilot facility to develop mRNA and RNA drugs and vaccines to combat disease and save lives.

The $96 million facilities, to be established in partnership with all NSW universities, will include laboratories and pre-clinical trial spaces that will enable early-stage RNA-based drug development. This is a significant milestone in the creation of the RNA ecosystem and future R&D commercialisation, with academics playing a major role in driving developments here in NSW for decades to come. The pilot facility will commence subject to the approval of a final business case.

The region’s Premier stated that the State Government’s funding for the facility aims to attract commercial investment in mRNA and RNA production here in Australia. He noted that the COVID pandemic has demonstrated to the world that it is critically important that we can develop vaccines quickly and for the country to have sovereign capability. He added that the advent of mRNA vaccines and the crucial role they’ve played in getting NSW back on the road to a pandemic recovery is just the beginning of what this incredible emerging medical technology can do.

The University of Sydney Vice-Chancellor and Principal was delighted that the University of Sydney is a founding partner on the facility which supports local mRNA and RNA drug and vaccine development. The University will contribute its world-leading expertise and infrastructure to the development and analysis of RNA-based medicines for COVID-19 and a range of other medical conditions.

The Treasurer felt that the facility would be an investment in NSW’s position as a global force in medical research and therapeutics. Supporting the development of high-growth emerging industries such as RNA therapeutics allows the region to not only lead the way in the fight against disease but to boost productivity through innovation and create high-skilled jobs for the future.

The Parliamentary Secretary to the Premier said that the NSW government’s Accelerating R&D in NSW Action Plan will lead future industries and jobs by building strong partnerships between local universities & industry. The NSW government has already announced the formation of the NSW RNA Bioscience Alliance which brings together the best and brightest at the region’s leading universities and research institutes to advance RNA research, development and manufacturing.

The Convener of the NSW Vice-Chancellors’ Committee stated that the investment in the pilot facility is a significant signal that the NSW Government is considering a deeper investment in R&D capabilities that will, in turn, empower the pilot facility to become more commercially viable and attractive to industry investment.

The medical technology sector in Australia is worth $6.1 billion and employs over 36,000 people. Of these businesses, nearly 40 per cent are located in NSW; making the medical technology industry in NSW the largest in Australia. While the sector is growing, there are significant opportunities to accelerate this growth. It is estimated the medical technology industry has the potential to create an additional 28,000 jobs and $18 billion in the gross domestic product (GDP) nationally by 2025.

The NSW Department of Industry has consulted with medical technology stakeholders in the state to develop the NSW medical technology industry development strategy 2018. It consists of a set of five key strategy areas underpinned by initiatives to promote further growth and innovation in the industry. The strategy aims to:

  1. support industry in commercialising research and development
  2. grow exports and attract investment into the NSW medical technology sector
  3. support skills development
  4. improve connectivity and collaboration within the NSW medical technology industry
  5. improve the business environment.


Qlik’s vision is a data-literate world, where everyone can use data and analytics to improve decision-making and solve their most challenging problems. A private company, Qlik offers real-time data integration and analytics solutions, powered by Qlik Cloud, to close the gaps between data, insights and action. By transforming data into Active Intelligence, businesses can drive better decisions, improve revenue and profitability, and optimize customer relationships. Qlik serves more than 38,000 active customers in over 100 countries.


As a Titanium Black Partner of Dell Technologies, CTC Global Singapore boasts unparalleled access to resources.

Established in 1972, we bring 52 years of experience to the table, solidifying our position as a leading IT solutions provider in Singapore. With over 300 qualified IT professionals, we are dedicated to delivering integrated solutions that empower your organization in key areas such as Automation & AI, Cyber Security, App Modernization & Data Analytics, Enterprise Cloud Infrastructure, Workplace Modernization and Professional Services.

Renowned for our consulting expertise and delivering expert IT solutions, CTC Global Singapore has become the preferred IT outsourcing partner for businesses across Singapore.


Planview has one mission: to build the future of connected work. Our solutions enable organizations to connect the business from ideas to impact, empowering companies to accelerate the achievement of what matters most. Planview’s full spectrum of Portfolio Management and Work Management solutions creates an organizational focus on the strategic outcomes that matter and empowers teams to deliver their best work, no matter how they work. The comprehensive Planview platform and enterprise success model enables customers to deliver innovative, competitive products, services, and customer experiences. Headquartered in Austin, Texas, with locations around the world, Planview has more than 1,300 employees supporting 4,500 customers and 2.6 million users worldwide. For more information, visit


SIRIM is a premier industrial research and technology organisation in Malaysia, wholly-owned by the Minister​ of Finance Incorporated. With over forty years of experience and expertise, SIRIM is mandated as the machinery for research and technology development, and the national champion of quality. SIRIM has always played a major role in the development of the country’s private sector. By tapping into our expertise and knowledge base, we focus on developing new technologies and improvements in the manufacturing, technology and services sectors. We nurture Small Medium Enterprises (SME) growth with solutions for technology penetration and upgrading, making it an ideal technology partner for SMEs.


HashiCorp provides infrastructure automation software for multi-cloud environments, enabling enterprises to unlock a common cloud operating model to provision, secure, connect, and run any application on any infrastructure. HashiCorp tools allow organizations to deliver applications faster by helping enterprises transition from manual processes and ITIL practices to self-service automation and DevOps practices. 


IBM is a leading global hybrid cloud and AI, and consulting services provider, helping clients in more than 175 countries capitalize on insights from their data, streamline business processes, reduce costs and gain the competitive edge in their industries. Nearly 3,800 government and corporate entities in critical infrastructure areas such as financial services, telecommunications and healthcare rely on IBM’s hybrid cloud platform and Red Hat OpenShift to affect their digital transformations quickly, efficiently, and securely. IBM’s breakthrough innovations in AI, quantum computing, industry-specific cloud solutions and business services deliver open and flexible options to our clients. All of this is backed by IBM’s legendary commitment to trust, transparency, responsibility, inclusivity, and service. For more information, visit